5%咪喹莫特乳膏治疗基底细胞癌的疗效与安全性:一项随机对照试验荟萃分析的批判性评价
评论指出该研究问题重复、合并所有BCC类型及对照设置不合理、存在数据重复使用和隐蔽重复发表等问题。
要点
- 评论质疑合并所有BCC类型及对照设置,结论需谨慎解读。
核心结论
- 原文作者结论认为咪喹莫特显著改善组织学/复合清除率,可考虑作为BCC一线治疗。
- 评论指出该荟萃分析存在研究问题重复、合并所有BCC类型及对照设置不合理等问题,结论可靠性存疑。
研究设计与样本
- 设计为随机对照试验的荟萃分析,纳入组织学确诊的BCC患者,比较5%咪喹莫特乳膏与所有其他治疗(包括赋形剂、切除手术、冷冻手术、氟尿嘧啶及甲基氨基酮戊酸光动力疗法)。
临床怎么用
- 临床决策时应结合BCC亚型、病灶特征及患者耐受性个体化选择治疗,不宜直接依据该荟萃分析将咪喹莫特作为所有BCC的一线治疗。
- 需向患者说明咪喹莫特局部治疗可能增加不良事件风险。
局限性
- 评论指出研究问题重复,缺乏创新性。
- 将所有BCC类型合并进行荟萃分析不合理。
- 将活性治疗与赋形剂和其他活性治疗的混合对照进行比较不合理。
- 存在同一研究数据在荟萃分析中多次使用所致的偏倚风险。
- 发现隐蔽重复发表,进一步加剧误导性系统综述的泛滥。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Jia and He aimed 'to compare the efficacy and safety of imiquimod with other treatments in patients with basal cell carcinoma' (BCC). DESIGN AND INCLUSION CRITERIA: Meta-analysis of studies that included patients with histologically confirmed BCC treated with imiquimod 5% cream compared with all other treatments, including vehicle, excisional surgery, cryosurgery, fluorouracil and methyl aminolaevulinate photodynamic therapy. OUTCOMES: The main outcome measures included histological and composite clearance rates, success rates, complete response rates, tumour-free survival and adverse events. RESULTS: Thirteen studies with a total of 4265 patients were included in the review. Pooled analyses comparing imiquimod with all or any of the listed comparators, including vehicle, demonstrated higher histological clearance rates [risk ratio (RR) 9·28, 95% confidence interval (CI) 5·56-15·5; P < 0·001], higher composite clearance rates (RR 34·2, 95% CI 21·3, 55·1; P = 0·001), no significant difference in success rates (RR 0·98, 95% CI 0·89-1·08; P = 0·73), higher complete response rates (RR 3·15, 95% CI 1·55-6·38; P = 0·001), no significant difference in tumour-free survival (RR 1·15, 95% CI 0·98-1·35; P = 0·088) and increased incidence of adverse events (RR 2·00, 95% CI 1·39-2·88; P < 0·001). CONCLUSIONS: The authors state that 'imiquimod significantly exhibited benefit effect in improving the histological/composite clearance rates' compared with other treatments, and they suggest it could be used as the first-choice treatment for patients with BCC. COMMENT: The main concerns related to the article by Jia and He are that the research question is replicative, it makes little sense to combine all BCC types in a meta-analysis, and it also makes no sense to combine an active treatment against a combination of vehicle and other active treatments. There are also concerns about bias related to the use of the same study data more than once in a meta-analysis. Furthermore, we have identified an example of covert duplicate publication, which further compounds the profusion of misleading systematic reviews.
引用
- Olabi B, Tasker F, Williams HC, et al. 'Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial': a critical appraisal. Br J Dermatol. 2020. PMID: 31977075. doi:10.1111/bjd.18891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。